KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

A Y Zhang, H Thomas, S Begbie, L Cheung, K N Chi, S Chowdhury, M Frydenberg, C Herberstein, L G Horvath, A M Joshua, N J Lawrence, G Marx, J McCaffrey, R McDermott, R A McLaughlin, S A North, F Parnis, W Parulekar, D W Pook, M N Reaume, S K Sandhu, A Tan, T H Tan, A Thomson, F Vera-Badillo, S G Williams, R R Zielinski, M R Stockler, I D Davis, C J Sweeney

Ann Oncol 37(11) 1537-1548

PMID42607762
PMCID-
DOI10.1016/j.annonc.2026.07.412
发表日期2026-08-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: We previously reported that, at median follow-ups of 34 and 68 months, enzalutamide improved overall survival (OS) compared with a first-generation nonsteroidal antiandrogen (NSAA) when used with testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC). We now report longer-term outcomes with a focus on adverse events (AEs) and causes of death. PATIENTS AND METHODS: Participants with mHSPC were randomly assigned (1 : 1) to receive daily enzalutamide or NSAA in addition to testosterone suppression; concurrent early docetaxel was permitted at clinician discretion. OS was the primary endpoint; secondary endpoints included progression-free survival (PFS), cause-specific survival, duration of treatment, and AEs. RESULTS: At a median follow-up of 8.1 years (97 months), deaths occurred in 285 of 563 (51%) participants assigned enzalutamide versus 337 of 562 (60%) assigned NSAA. OS was longer with enzalutamide than with NSAA [median 7.9 versus 5.8 years; OS at 8 years 50% versus 40%; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.63-0.86, P = 0.0001]. Clinical PFS at 8 years also favoured enzalutamide (43% versus 20%; HR 0.49, 95% CI 0.42-0.57, P < 0.0001). Of the 622 deaths, 468 were attributed to prostate cancer, of which fewer were associated with enzalutamide than with NSAA (207 versus 261), whereas deaths attributed to other causes occurred with similar frequency in the two groups (78 versus 76). Median treatment duration was 4.8 years with enzalutamide and 1.9 years with NSAA. Of 185 of 563 (33%) participants still receiving enzalutamide at data cut-off, most (163 of 185, 88%) remain on the full 160-mg dose. Rates of grade 3-5 AEs per 100 person-years were similar between groups for cardiac (2.2 versus 2.2) and nervous system disorders (2.3 versus 2.0), with more falls observed with enzalutamide (0.70 versus 0.24). CONCLUSION: Enzalutamide continues to provide substantial long-term OS benefit at 8 years, with sustained efficacy, maintenance of full dose in most participants, and no increase in non-prostate cancer mortality.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。